Estée Lauder Companies vs Galderma

8-K Financial Filing Analysis for Estée Lauder Companies (2026-11-02)

On November 2, 2026, The Estée Lauder Companies Inc. filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing its financial results for the fiscal first quarter ended September 30, 2026. The announcement, furnished via an accompanying press release (Exhibit 99.1), also provided updated management outlook and guidance for fiscal full-year 2027 net sales and diluted net earnings per common share. The filing was executed by Executive Vice President and Chief Financial Officer Akhil Shrivastava.

• Estée Lauder Companies furnished Item 2.02 disclosures reporting financial results for the fiscal quarter ended September 30, 2026.
• The furnished press release (Exhibit 99.1) includes management guidance estimates for fiscal year 2027 net sales and diluted net earnings per common share.
• The filing was executed on November 2, 2026, by Akhil Shrivastava, Executive Vice President and Chief Financial Officer.

10-Q Financial Filing Analysis for Estée Lauder Companies (2026-11-02)

The Estée Lauder Companies Inc. reported Q1 FY2027 net sales of $3,715 million, representing a 7% year-over-year increase (6% in constant currency), driven by volume growth across all geographic regions and led by Fragrance (+19%) and Skin Care (+5%). Operating income surged 141% to $408 million, while gross margin expanded 230 basis points to 75.7%, propelled by favorable business mix, strategic pricing, and cost efficiencies from the Profit Recovery and Growth Plan (PRGP). Net earnings rose nearly fourfold to $233 million ($0.64 per diluted share), supported by a lower effective tax rate of 32.5% versus 56.9% in the prior-year quarter. Cash and cash equivalents stood at $3,198 million, with operating cash outflows narrowing to $166 million.

• Net sales grew 7% year-over-year to $3,715 million for the quarter ended September 30, 2026, while gross margin expanded 230 basis points to 75.7%.
• Operating income increased to $408 million from $169 million, and diluted net earnings per share climbed to $0.64 from $0.13.
• On October 5, 2026, the company completed the acquisition of the remaining 51% stake in Forest Essentials (Mountain Valley Springs India) for $160 million in cash, which is expected to yield a $94 million fair-value remeasurement gain in Q2 FY2027.

8-K Financial Filing Analysis for Estée Lauder Companies (2026-11-04)

On November 4, 2026, The Estée Lauder Companies Inc. hosted its Capital Markets Experience: China Ecosystem Immersion event in Shanghai, China, furnishing presentations and a press release under Item 7.01 (Regulation FD). During the event, management outlined its fiscal 2030 corporate ambitions and presented a comprehensive long-term roadmap intended to drive sustainable revenue growth and enhance profitability. The strategic updates spanned core global brands and categories, highlighting targeted initiatives across key luxury skincare, makeup, fragrance, and travel retail operations, with an emphasis on reinforcing consumer engagement and brand equity within the Chinese ecosystem.

• The Estée Lauder Companies announced its long-term fiscal 2030 ambition during a Capital Markets Experience event held in Shanghai, China on November 4, 2026.
• Presentations (Exhibits 99.1 to 99.10) covered comprehensive growth roadmaps across key brands including Estée Lauder, La Mer, M·A·C, The Ordinary, luxury fragrance, and travel retail.
• The filing was furnished under Item 7.01 Regulation FD Disclosure and signed by Executive Vice President and Chief Financial Officer Akhil Shrivastava.

Fall Clinical 2026: Galderma presents new three-year Nemluvio® data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older

Galderma's latest press release announces new three-year data for Nemluvio® in atopic dermatitis, presented at Fall Clinical 2026.

EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis

Galderma announced new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) provides sustained improvements in moderate-to-severe atopic dermatitis for up to 152 weeks. At Week 152, up to 91% of patients achieved EASI-75, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life. The findings were presented at the EADV 2026 Congress in Vienna, Austria, which runs September 30 to October 3, 2026. Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis in more than 40 countries.

• Galderma published the press release on September 30, 2026, announcing new three-year ARCADIA long-term extension data for Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis.
• At Week 152, up to 91% of patients achieved EASI-75, up to 75% achieved EASI-90, up to 67% achieved IGA 0/1, up to 88% achieved clinically meaningful itch relief, and up to 92% achieved clinically meaningful quality-of-life improvement.
• The findings were presented at the EADV 2026 Congress in Vienna, Austria, with the oral presentation scheduled for Thursday, October 1, 2026.

Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies

Galderma has been added to the Swiss Market Index (SMI), marking its inclusion among Switzerland's leading blue-chip companies. This is a major corporate milestone for the company.